drugset
drugset / Trial / NCT00345787

Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain

NCT00345787 ↗

Phase 3 Completed 262 enrolled Mundipharma K.K.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy and safety of BTDS compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee.

Timeline

Start
2006-05
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 5 mg Other
Subject Buprenorphine Other / unclassified 10 mg Other
Subject Buprenorphine Other / unclassified 20 mg Other

Indications

osteoarthritis